Tom Boterberg

Tom Boterberg

Auto-generated profile, based on publicly available information

Tom Boterberg

Department of Human Structure and Repair, Ghent University, 9000 Ghent, Belgium

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LPLies Pottel
Lies Pottel
MLMichelle Lycke
Michelle Lycke
TBTom Boterberg
Tom Boterberg
HPHans Pottel
Hans Pottel
LGLaurence Goethals
Laurence Goethals
Philip Robert DebruynePhilip Robert Debruyne
Philip Robert Debruyne
Evidence-based guidelines concerning the older head and neck cancer (HNCA) patient are lacking. Accurate patient selection for optimal care management is therefore challenging. We examined if geriatric assessment is indicative of long-term health-related quality of life (HRQOL) and overall survival in this unique population. All HNCA patients, aged ≥65 years, eligible for curative radio(chemo)therapy were evaluated with the Geriatric-8 (G-8) questionnaire and a comprehensive geriatric assessment (CGA). Euroqol-5 dimensions (EQ-5D) and survival were collected until 36 months post treatment start. Repeated measures ANOVA was applied to analyse HRQOL evolution in ‘fit’ and ‘vulnerable’ patients, defined by G-8. Kaplan-Meier curves and cox proportional hazard analysis were established for determination of the prognostic value of geriatric assessments. Quality-adjusted survival was calculated in both patient subgroups. One hundred patients were recruited. Seventy-two percent of patients were considered vulnerable according to CGA (≥2 abnormal tests). Fit patients maintained a relatively acceptable long-term HRQOL, whilst vulnerable patients showed significantly lower median health states. The difference remained apparent at 36 months. Vulnerability, as classified by G-8 or CGA, came forward as independent predictor for lower EQ-5D index scores. After consideration of confounders, a significantly lower survival was observed in patients defined vulnerable according to G-8, compared to fit patients. A similar trend was seen based on CGA. Calculation of quality-adjusted survival showed significantly less remaining life months in perfect health in vulnerable patients, compared to fit ones. G-8 is indicative of quality-adjusted survival, and should be considered at time of treatment decisions for the older HNCA patient.

1 February 2017 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
HKHeidi V.N. Küsters-Vandevelde
Heidi V.N. Küsters-Vandevelde
VKVibeke Kruse
Vibeke Kruse
TMTom Van Maerken
Tom Van Maerken
TBTom Boterberg
Tom Boterberg
RPRolph Pfundt
Rolph Pfundt
WBWilleke Blokx
Willeke Blokx

30 May 2019 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
JVJeroen Verhoeven
Jeroen Verhoeven
JBJulie Bolcaen
Julie Bolcaen
VMValerie de Meulenaere
Valerie de Meulenaere
KKKen Kersemans
Ken Kersemans
BDBenedicte Descamps
Benedicte Descamps
IGIngeborg Goethals
Ingeborg Goethals
Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost importance for guiding RT. In this project we investigated the feasibility and treatment response of subvolume boosting to a PET-defined tumor part. F98 GB cells inoculated in the rat brain were imaged using T2- and contrast-enhanced T1-weighted (T1w) MRI. A dose of 20 Gy (5 × 5 mm2) was delivered to the target volume delineated based on T1w MRI for three treatment groups. Two of those treatment groups received an additional radiation boost of 5 Gy (1 × 1 mm2) delivered to the region either with maximum [18F]FET or [18F]FAZA PET tracer uptake, respectively. All therapy groups received intraperitoneal (IP) injections of TMZ. Finally, a control group received no RT and only control IP injections. The average, minimum and maximum dose, as well as the D90-, D50- and D2- values were calculated for nine rats using both RT plans. To evaluate response to therapy, follow-up tumor volumes were delineated based on T1w MRI. When comparing the dose volume histograms, a significant difference was found exclusively between the D2-values. A significant difference in tumor growth was only found between active therapy and sham therapy respectively, while no significant differences were found when comparing the three treatment groups. In this study we showed the feasibility of PET guided subvolume boosting of F98 glioblastoma in rats. No evidence was found for a beneficial effect regarding tumor response. However, improvements for dose targeting in rodents and studies investigating new targeted drugs for GB treatment are mandatory.

2 February 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
Laura TackLaura Tack
Laura Tack
AMAnn-Sophie Maenhoudt
Ann-Sophie Maenhoudt
LKLore Ketelaars
Lore Ketelaars
JZJolien De Zutter
Jolien De Zutter
SPStefanie Pinson
Stefanie Pinson
Philip Robert DebruynePhilip Robert Debruyne
Philip Robert Debruyne
Depression is a common and disabling disorder in later life, particularly among people with poor physical health. There are many screening tools available that can be used to examine depressive symptoms; however, not all of them may be appropriate or accurate for older adults with cancer. This pilot study was designed to test the diagnostic performance of two screening tools and their short versions in a cohort of vulnerable (G8 score ≤ 14/17) older patients with cancer undergoing comprehensive geriatric assessment (CGA). The prospective analysis covered 50 vulnerable patients with cancer aged ≥70 years. The diagnostic performance of the Geriatric Depression Scale (GDS)-15, GDS-4, Patient Health Questionnaire (PHQ)-9 and PHQ-2 was compared to the ‘gold standard’ Structured Clinical Interview for DSM-5 Disorders (SCID-5-S) depression module A. The sensitivity and specificity in detecting depressive symptoms were the highest in the case of PHQ-2, with an area under the receiver operating characteristic curve (AUROC) of 92.7%. The AUROC for the 9-item version, PHQ-9, was 90.2%. For the GDS-15 and GDS-4, the AUROC was only 56.2% and 62.0%, respectively. The SCREEN pilot study illustrates the potential benefit of using a shorter screening tool, PHQ-2, to identify older patients with cancer who would benefit from a more in-depth emotional evaluation as part of a CGA.

22 August 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Laura TackLaura Tack
Laura Tack
LMLore Mertens
Lore Mertens
MVMarte Vandeweyer
Marte Vandeweyer
FFFien Florin
Fien Florin
EPEmma Pauwels
Emma Pauwels
Philip Robert DebruynePhilip Robert Debruyne
Philip Robert Debruyne
Approximately one-third of cancer survivors report a need for professional help to cope with Fear of Cancer Recurrence (FCR). In the REMOTE trial, we aim to investigate the efficacy of two internet-based mind-body techniques to address this currently unmet medical need. Cancer survivors, screened using the Cancer Worry Scale (CWS), are randomly assigned to one of the three study groups: (1) internet-based emotional freedom techniques (iEFT) (n = 113), (2) an active control condition internet-based mindfulness meditation intervention (iMMI) (n = 113), or (3) a wait-list control group (WLC) (n = 113). The interventions iEFT and iMMI are conducted remotely using Microsoft Teams (Microsoft, Redmond, WA), and participants have access to an online platform via the MyNexuzHealth application (nexuzhealth NV, Hasselt, Belgium). The primary endpoint is the level of FCR. Secondary outcomes are emotional distress and quality of life (QoL). If iEFT and/or iMMI appear to be effective in reducing FCR, they could be readily implemented in clinical practice.

14 July 2017
Verified
Book Chapter
Closed access
PDF file
MLMichelle Lycke
Michelle Lycke
LPLies Pottel
Lies Pottel
TBTom Boterberg
Tom Boterberg
SMSupriya G. Mohile
Supriya G. Mohile
EBEtienne Brain
Etienne Brain
Philip Robert DebruynePhilip Robert Debruyne
Philip Robert Debruyne
This chapter discusses: current evidence in the field of aging and cancer; the integration of geriatric principles in oncology; the content of a Comprehensive Geriatric Assessment; Comprehensive Geriatric Assessment in routine practice; international perspective. Due to growth of the aging population and a prolonged exposure to carcinogens, cancer has become an important disease in older people. Cancer is a very serious health problem at any age; however, combined with increasing age, it creates even more challenging situations for healthcare providers. Medical and radiation oncologists are faced with another challenge since evidence-based data of the risks and benefits of cancer treatments in older patients are lacking. Up to 40 per cent of general geriatric patients are found to be at risk for malnutrition, and without proper nutritional support, an intensive cancer treatment could induce cachexia. The incidence of cancer, particularly gynaecologic malignancy, increases with advanced age.